INSM earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -18.55. Updated 2026-07-23.
Insmed (INSM) Research Hub
Insmed (INSM) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 129.41 USD (+0.47%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -18.55, market cap 23.01B. This hub links to the full technical, earnings and options research available for INSM.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 129.41 USD (+0.47%) |
| 52-week range | 94.22 USD – 137.7 USD |
| Trend regime | Range |
| 14-day RSI | 47.9 (Neutral) |
| Trailing P/E | -18.55 |
| Market cap | 23.01B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for INSM
Covered Call on INSM: how it works, illustrative setup around the real 129.41 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on INSM: how it works, illustrative setup around the real 129.41 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on INSM: how it works, illustrative setup around the real 129.41 USD price, max profit/loss, breakeven and when to use it. Educational.
INSM technical analysis: range, last 129.41 USD, RSI 47.9, 52w range 94.22 USD–137.7 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is INSM in?
Insmed (INSM) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is INSM in an uptrend or downtrend?
As of 2026-09-11, INSM is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is INSM's trailing P/E ratio?
INSM's trailing P/E is -18.55, with a market cap of 23.01B. See the earnings research page for full valuation detail.
When does INSM next report earnings?
INSM is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.7 USD.